What is the appropriate workup and treatment for a patient with hypercalcemia (elevated total and ionized calcium)?

Workup and Treatment of Hypercalcemia

For a patient with elevated total and ionized calcium, immediately measure intact parathyroid hormone (PTH) to distinguish PTH-dependent from PTH-independent causes, while simultaneously initiating aggressive intravenous normal saline hydration if calcium is ≥12 mg/dL or the patient is symptomatic. 1, 2

Initial Diagnostic Workup

Essential First-Line Laboratory Tests

• Measure intact PTH immediately—this single test is the most important to differentiate primary hyperparathyroidism (elevated or inappropriately normal PTH) from malignancy and other causes (suppressed PTH <20 pg/mL). 1, 3, 4

• Calculate corrected calcium using the formula: Corrected calcium (mg/dL) = Total calcium + 0.8 × [4.0 - Serum albumin (g/dL)] to account for hypoalbuminemia. 1, 2

• Measure ionized calcium directly (normal: 4.65-5.28 mg/dL) for definitive assessment, as corrected calcium formulas can be inaccurate and ionized calcium is what parathyroid cells actually sense. 1, 3, 5

• Obtain serum creatinine, BUN, and eGFR to assess renal function, as CKD significantly alters calcium metabolism and PTH interpretation. 1, 3

Additional Diagnostic Tests Based on PTH Result

If PTH is elevated or inappropriately normal (PTH-dependent hypercalcemia):

• Measure 25-hydroxyvitamin D to exclude vitamin D deficiency causing secondary hyperparathyroidism (target >20 ng/mL). 1, 3
• Check serum phosphorus (typically low-normal in primary hyperparathyroidism). 3
• Obtain 24-hour urine calcium or spot urine calcium/creatinine ratio to assess hypercalciuria. 3
• Consider renal ultrasound to evaluate for nephrocalcinosis or kidney stones. 3

If PTH is suppressed (<20 pg/mL) (PTH-independent hypercalcemia):

• Measure PTH-related protein (PTHrP)—elevated in the majority of malignancy-associated hypercalcemia cases. 1, 3
• Measure both 25-hydroxyvitamin D AND 1,25-dihydroxyvitamin D together to distinguish vitamin D intoxication (markedly elevated 25-OH) from granulomatous disease like sarcoidosis (low 25-OH but elevated 1,25-OH due to extrarenal 1α-hydroxylase activity). 1, 3
• If PTHrP is elevated, obtain immediate comprehensive imaging: chest CT, abdominal/pelvic CT or MRI, and PET-CT when available, as median survival is approximately 1 month after detection. 3
• For suspected multiple myeloma, perform serum protein electrophoresis, immunofixation, free light-chain assay, and consider bone marrow biopsy. 1

Critical Measurement Considerations

• Use EDTA plasma rather than serum for PTH measurement and keep samples at 4°C, as PTH is most stable under these conditions. 3
• Ensure fasting samples for diagnostic purposes, as calcium supplements or calcium-containing nutrients cause transient elevations lasting several hours. 5
• Discontinue biotin supplements at least 72 hours before PTH testing, as biotin interferes with immunoassays and causes under- or over-estimation. 3
• PTH assays vary by up to 47% between different generations—always use assay-specific reference ranges. 3

Severity Stratification and Urgency

• Mild hypercalcemia: Total calcium 10.2-12 mg/dL—usually asymptomatic but may cause fatigue and constipation in 20% of patients. 1, 4
• Moderate hypercalcemia: Total calcium 12-14 mg/dL—requires prompt intervention with hydration and bisphosphonates. 1, 2
• Severe hypercalcemia: Total calcium ≥14 mg/dL or ionized calcium ≥10 mg/dL—causes nausea, vomiting, dehydration, confusion, somnolence, coma, and cardiac dysrhythmias; requires emergency treatment. 1, 6, 4

Acute Treatment Algorithm

Step 1: Immediate Hydration (All Moderate-to-Severe Cases)

• Administer aggressive IV normal saline to correct hypovolemia and promote calciuresis, targeting urine output of 100-150 mL/hour. 1, 2, 3
• Balanced crystalloids are preferred over 0.9% saline when possible to avoid hyperchloremic metabolic acidosis with large volumes. 1
• Avoid loop diuretics (furosemide) until complete volume repletion is achieved—premature use worsens dehydration and hypercalcemia. 1, 3
• Loop diuretics should only be added after full volume repletion and only in patients with cardiac or renal insufficiency to prevent fluid overload. 1, 3

Step 2: Definitive Pharmacologic Treatment

For moderate-to-severe hypercalcemia (calcium ≥12 mg/dL):

• Administer zoledronic acid 4 mg IV infused over ≥15 minutes as the preferred bisphosphonate—superior to pamidronate, normalizing calcium in approximately 50% of patients by day 4. 1, 2, 3
• Bisphosphonate therapy may be initiated early without waiting for complete rehydration. 1
• Check serum creatinine before each bisphosphonate dose; withhold if renal function deteriorates (increase >0.5 mg/dL from normal baseline or >1.0 mg/dL from abnormal baseline). 1, 3
• Dose adjustments required for creatinine clearance <60 mL/min. 1

For patients with impaired renal function (eGFR <30 mL/min or CrCl <60 mL/min):

• Use denosumab 120 mg subcutaneously instead of bisphosphonates—lower rates of renal toxicity but higher risk of hypocalcemia. 1, 3
• Provide calcium supplementation (500 mg daily) plus vitamin D (400 IU daily) during denosumab treatment to prevent hypocalcemia. 1

For rapid calcium reduction (bridge therapy):

• Administer calcitonin-salmon 4 International Units/kg subcutaneously or intramuscularly every 12 hours—provides rapid onset within hours but limited efficacy and tachyphylaxis develops within 48 hours. 1, 7
• If response is unsatisfactory after 1-2 days, increase to 8 International Units/kg every 12 hours; maximum dose is 8 International Units/kg every 6 hours. 7

Step 3: Etiology-Specific Treatment

For granulomatous disease (sarcoidosis), lymphoma, vitamin D intoxication, or multiple myeloma:

• Administer prednisone 20-40 mg/day orally or methylprednisolone IV equivalent—corticosteroids reduce excessive intestinal calcium absorption. 1, 3
• Allow 3-6 months to demonstrate responsiveness before considering escalation. 1

For severe hypercalcemia with renal failure:

• Initiate hemodialysis with calcium-free or low-calcium dialysate (1.25-1.50 mmol/L) when pharmacologic measures fail or are contraindicated. 1, 3

Step 4: Medication Adjustments

• Immediately discontinue all calcium supplements, vitamin D supplements (including ergocalciferol, cholecalciferol, calcitriol, paricalcitol), calcium-based phosphate binders, and thiazide diuretics. 1, 3
• Avoid NSAIDs and intravenous contrast media in patients with renal impairment. 1

Monitoring During Acute Treatment

• Measure ionized calcium every 4-6 hours during the first 48-72 hours, then twice daily until stable. 1, 3
• Check serum calcium, phosphorus, potassium, magnesium, and renal function every 6-12 hours initially. 1, 2
• Obtain immediate 12-lead ECG to identify shortened QT interval (hypercalcemia) or arrhythmias, especially if calcium ≥14 mg/dL. 1
• Target corrected calcium of 8.4-9.5 mg/dL, preferably at the lower end of this range. 1, 3
• Maintain calcium-phosphorus product <55 mg²/dL² to prevent soft tissue calcification. 1, 3

Definitive Management Based on Etiology

Primary Hyperparathyroidism (Elevated or Normal PTH with Hypercalcemia)

Surgical indications for parathyroidectomy:

• Corrected calcium >1 mg/dL above upper limit of normal 3
• Age <50 years 3
• eGFR <60 mL/min/1.73 m² 3
• Osteoporosis (T-score ≤-2.5 at any site) 3
• History of nephrolithiasis or nephrocalcinosis 3
• 24-hour urinary calcium >300 mg/24 hours 3
• Disabling neuropsychiatric symptoms (depression, cognitive impairment, "brain fog") 3

Refer to both endocrinology and a high-volume parathyroid surgeon for all patients meeting surgical criteria, as outcomes are significantly better with specialized expertise. 3

For non-surgical candidates:

• Maintain normal dietary calcium intake (1000-1200 mg/day)—do not restrict. 3
• Ensure 25-hydroxyvitamin D >20 ng/mL with supplementation if needed. 3
• Monitor serum calcium every 3 months. 3

Malignancy-Associated Hypercalcemia (Suppressed PTH, Elevated PTHrP)

• Median survival is approximately 1 month—do not delay imaging or oncology consultation while treating hypercalcemia. 3
• Treat underlying malignancy when possible. 1
• Continue bisphosphonate therapy for up to 2 years in patients with multiple myeloma or bone metastases. 1

Common Pitfalls to Avoid

• Do not rely on corrected calcium alone—measure ionized calcium for definitive diagnosis, as correction formulas can be inaccurate. 1, 3
• Do not order parathyroid imaging before confirming biochemical diagnosis—imaging is for surgical planning, not diagnosis. 3
• Do not supplement vitamin D until hypercalcemia resolves, even if 25-OH vitamin D is low, as supplementation worsens calcium elevation. 1, 3
• Do not use calcitriol or active vitamin D analogs in primary hyperparathyroidism—they increase intestinal calcium absorption and exacerbate hypercalcemia. 3
• Do not use corticosteroids for solid-tumor malignancies—they are ineffective and reserved only for lymphoma, multiple myeloma, granulomatous disease, or vitamin D intoxication. 1
• Do not delay bisphosphonate therapy in moderate-to-severe hypercalcemia—temporary measures like calcitonin provide only 1-4 hours of benefit with rebound. 1